Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Lung Neoplasms 23Carcinoma, Non-Small-Cell Lung 16Ovarian Neoplasms 13Fallopian Tube Neoplasms 12Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Melanoma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Triple Negative Breast Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Mycosis Fungoides 5Endometrial Neoplasms 5Breast Neoplasms 5Lymphoma, T-Cell, Cutaneous 4Glioblastoma 4Thyroid Neoplasms 3Sezary Syndrome 3Nasopharyngeal Carcinoma 3Multiple Myeloma 3Mouth Neoplasms 3Lymphoma, T-Cell 3Colonic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma 3Brenner Tumor 3Brain Neoplasms 3

Interventions

Sirolimus 2temsirolimus 1carbon-11 acetate 1Valproic Acid 1Respiratory Function Tests 1Phlebotomy 1Immunoglobulin G 1Imatinib Mesylate 1Genetic Testing 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphangioleiomyomatosis × Immunoglobulin G × 1 year × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡